Slow Capital Inc. Has $9.09 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Slow Capital Inc. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,765 shares of the biopharmaceutical company’s stock after purchasing an additional 410 shares during the quarter. Regeneron Pharmaceuticals makes up about 1.3% of Slow Capital Inc.’s holdings, making the stock its 17th biggest position. Slow Capital Inc.’s holdings in Regeneron Pharmaceuticals were worth $9,093,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at about $26,000. Fairfield Financial Advisors LTD bought a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $37,000. Truvestments Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $39,000. Finally, Valley Wealth Managers Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $49,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.3 %

Shares of REGN stock opened at $684.71 on Tuesday. The business has a fifty day simple moving average of $727.19 and a 200-day simple moving average of $936.01. The stock has a market cap of $75.24 billion, a P/E ratio of 16.94, a P/E/G ratio of 1.59 and a beta of 0.10. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $666.25 and a fifty-two week high of $1,211.20.

Analyst Ratings Changes

REGN has been the topic of a number of research analyst reports. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Evercore ISI lowered their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Finally, Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,006.71.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.